Literature DB >> 12892390

Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies.

J Chapman1, J H Rand, R L Brey, S R Levine, I Blatt, M A Khamashta, Y Shoenfeld.   

Abstract

Although many types of neurological disorders and events have been described in association with antiphospholipid antibodies (aPL) and the antiphospholipid syndrome (APS), only ischaemic stroke is reasonably well established and accepted as a diagnostic criterion for the syndrome. We propose to evaluate, classify and rank the association of other neurological manifestations as possible, probable, or definite according to the data available from clinical studies and animal models. By these criteria, none of the neurological disorders or events such as epilepsy, psychiatric disease, dementia, transverse myelitis, multiple sclerosis-like disease, chorea, migraine, Guillian-Barrè syndrome, and sensory-neural hearing loss, can be definitely associated with aPL or APS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892390     DOI: 10.1191/0961203303lu392oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

Review 1.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

2.  STEMI of the anterior wall associated with Sneddon's syndrome.

Authors:  S Scheuermann; C Schlundt
Journal:  Herz       Date:  2013-05-19       Impact factor: 1.443

Review 3.  Cognitive impairment in antiphospholipid syndrome: evidence from animal models.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Caio Rodrigues Guirau; Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2012-01-05       Impact factor: 2.980

4.  Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome.

Authors:  I Krause; S Lev; A Fraser; M Blank; M Lorber; L Stojanovich; J Rovensky; J Chapman; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-03-18       Impact factor: 19.103

Review 5.  Cognitive dysfunction and antiphospholipid antibodies.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Jozélio Freire de Carvalho; Fernando Augusto Peres; Yehuda Shoenfeld
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

6.  Antiphospholipid antibodies in patients with sensorineural hearing loss.

Authors:  Edgar Bachor; Stephan Kremmer; Ernst Kreuzfelder; Klaus Jahnke; Said Seidahmadi
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-02-25       Impact factor: 2.503

Review 7.  Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature.

Authors:  Pikman Regina; Rotman Pnina; Aiman Natur; Levy Yair
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

8.  Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome.

Authors:  R Weiss; A Bitton; L Nahary; M T Arango; I Benhar; M Blank; Y Shoenfeld; J Chapman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  Mania: psychiatric manifestations of the antiphospholipid syndrome.

Authors:  Haniya Raza; Steven A Epstein; Maryland Pao; Donald L Rosenstein
Journal:  Psychosomatics       Date:  2008 Sep-Oct       Impact factor: 2.386

Review 10.  Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome.

Authors:  O Shovman; B Gilburd; O Barzilai; P Langevitz; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.